Generics BulletinThe US Federal Trade Commission’s second round of challenges to Orange Book-listed drug product patents moves the battle over listing criteria into the high-profile diabetes and weight loss therapeuti
Pink SheetThe US Federal Trade Commission’s second round of challenges to Orange Book-listed drug product patents moves the battle over listing criteria into the high-profile diabetes and weight loss therapeuti
Pink SheetThe Federal Trade Commission is planning to announce preliminary results from its ongoing in-depth investigation of potentially anti-competitive behavior in the pharmacy benefit manager industry much
Pink SheetThe US Federal Trade Commission broke new ground in sending letters to 10 drug manufacturers claiming they improperly listed patents in the US Food and Drug Administration’s Orange Book. The agency di